Boro-Scopol N

Quick links

Choose a section

Quick links to important sections

Advertisements

Boro-Scopol N

Advertisements
Advertisements

Overview of Boro-Scopol N

Property Description
Active Ingredient Hyoscine Butylbromide (Scopolamine Butylbromide)
Form Oral tablets and solution for injection
Pharmacological Class Antispasmodic Agent; Anticholinergic
Common Use Relief of painful muscle spasms in the abdomen
Origin Semisynthetic derivative (of a tropane alkaloid)

Boro-Scopol N is a medicinal product defined by its active pharmaceutical ingredient, Hyoscine Butylbromide, and is classified primarily as an Antispasmodic Agent, falling under the broader class of Anticholinergic drugs. This class of medication is designed specifically to relieve acute, painful muscle contractions—known as spasms—in the body's internal, involuntary organs. Hyoscine Butylbromide is a clinically recognized therapeutic agent used for these indications.


Composition, Origin, and Available Forms

The active ingredient is a semisynthetic derivative of the naturally occurring tropane alkaloid Hyoscine. The substance is engineered as a Quaternary Ammonium Compound, a structural modification that ensures its therapeutic action remains largely confined to the periphery. This design restricts the drug's ability to cross the Blood-Brain Barrier (BBB), thereby directing its effect toward the spasm's source. Boro-Scopol N is typically presented in two high-level dosage forms: oral tablets and a sterile solution for injection.


What is the General Purpose of an Antispasmodic Agent?

The general purpose of Boro-Scopol N is to provide rapid and targeted smooth muscle relaxation to alleviate the acute discomfort of visceral spasms. By acting as an Antimuscarinic Agent, the drug competitively blocks the effects of the neurotransmitter Acetylcholine on the muscles of the internal organs. This blockade halts the signal that initiates the spasm, resulting in the muscle softening and relaxing, which ultimately relieves the intense, sharp pain associated with conditions characterized by muscle overactivity, such as those that can occur during episodes of renal or biliary colic. The drug’s primary action is peripheral antimuscarinic, meaning it directly calms overactive muscles in the gut and abdomen rather than acting on the central nervous system.

Advertisements

What side effects are possible with Boro-Scopol N?

Possible side effects and safety information

The safety profile of Boro-Scopol N (Hyoscine Butylbromide) is based on established regulatory classifications derived from clinical trials and post-marketing surveillance, consistent with its action as an anticholinergic agent.

Adverse Reactions by Frequency

Adverse reactions are classified by frequency as defined in official regulatory documents. The most frequently documented effects are related to the drug's antispasmodic action on different body systems.

Frequency Classification Officially Documented Reactions
Common (1/100 to < 1/10) Accommodation disorders (transient impaired near vision), Tachycardia (increased heart rate).
Uncommon (1/1,000 to < 1/100) Dry mouth, Dyshidrosis (abnormal sweating), and skin reactions (e.g., Urticaria, Pruritus).
Rare (1/10,000 to < 1/1,000) Urinary retention.
Not Known (Frequency cannot be estimated) Anaphylactic shock, Dyspnoea, Blood pressure decreased.

Serious Adverse Reactions and Safety Constraints

The official safety profile highlights the risk of Serious Hypersensitivity Reactions, including Anaphylactic Shock, which are documented in post-marketing reports, particularly following the injectable route of administration. These reactions are classified as having a frequency that is Not Known.

Regulatory documents establish explicit limitations on use. The medicine is formally contraindicated (should not be used) in individuals with specific pre-existing conditions that increase risk, such as untreated narrow-angle glaucoma, prostatic hypertrophy (or other conditions causing urinary retention), Myasthenia Gravis, and certain types of gastrointestinal obstruction (e.g., paralytic ileus).

Population Safety Notes explicitly state that older adults may be more susceptible to anticholinergic side effects like urinary retention. Furthermore, specific adverse effects such as Hypotension and Anaphylaxis are explicitly noted to occur most often after parenteral administration (injection).

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This section reflects the officially documented overdose profile of Boro-Scopol N (Hyoscine Butylbromide), as stated in government regulatory sources. Overdose typically presents as an exaggeration of the drug's anticholinergic effects.

Manifestations of Overdose Severe or Life-Threatening Outcomes
Tachycardia, hypotension, dry mouth, difficulty passing urine (impaired micturition), reddening of the skin (flushing), and sight disturbances. Cardiac arrest, acute myocardial infarction, and fatal outcome are documented, particularly in patients with pre-existing cardiac disease.
Drowsiness, confusion, and agitation are documented in rare instances, especially following parenteral administration. Anaphylaxis and coma are also listed as rare but severe outcomes.

Mandatory Emergency Action

The regulatory guidance requires urgent medical attention if an overdose is suspected. Individuals must immediately call a POISON CENTER or doctor or seek medical care right away, even if no immediate symptoms are present.

Overdose management is symptomatic and supportive treatment and requires specific medical surveillance. Due to the documented risk, monitoring and availability of resuscitation equipment are emphasized, especially for patients with underlying cardiac disease.

Advertisements

Therapeutic Uses of Boro-Scopol N

Boro-Scopol N's therapeutic domain is applied across domains where additional symptomatic support is needed for symptoms related to physical discomfort and symptoms of increased neurological or muscular activity. This focus is particularly relevant in the management of symptoms associated with acute or episodic changes.

The core purpose of this approach is to help address symptom clusters that may become intense or disruptive. For instance, it is commonly used across conditions presenting with acute episodes such as painful stomach and bowel cramps, including those linked with Irritable Bowel Syndrome (IBS), bladder spasms, and period pain. This supportive role is relevant in contexts involving heightened systemic burden.

In the context of managing symptoms related to physical discomfort and spasms, Boro-Scopol N contributes to improved comfort during periods of heightened symptoms. This supportive relief assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations that interfere with daily functioning. This approach supports general well-being during symptomatic phases. It is applied in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is needed.

Quick Fact: May assist with symptoms related to physical discomfort

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Boro-Scopol N? — Official Regulatory Information

The eligibility for Boro-Scopol N (Hyoscine Butylbromide) is strictly defined by regulatory bodies and centers on the drug's potential to exacerbate certain pre-existing conditions.

Populations for Whom Use is Contraindicated

Use of Boro-Scopol N is strictly prohibited (contraindicated) for individuals with specific conditions, primarily due to the risk of complications related to its anticholinergic action. These absolute exclusions include:

  • Gastrointestinal Obstruction: Mechanical stenosis, paralytic or obstructive ileus, and megacolon.
  • Eye and Cardiovascular Conditions: Untreated narrow-angle glaucoma and tachycardia (pathological rapid heart rhythm).
  • Other Conditions: Myasthenia gravis, prostatic hypertrophy with urinary retention, and known hypersensitivity to the active ingredient or excipients.

Age- and Condition-Based Restrictions

Population Group Regulatory Status
Children under 6 years Not recommended due to insufficient established data.
Pregnancy/Lactation Not recommended as safety is not established by regulatory data.
Severe Organ Impairment Contraindicated in severe hepatocellular insufficiency (Child-Pugh C). Use with caution in severe renal or mild-to-moderate hepatic impairment.

For adults and children aged 6 to 12 (with specific dosing for tablets), the medicine is an approved option. The injection formulation is also contraindicated for patients receiving anticoagulant drugs if administered intramuscularly.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify interaction patterns for Boro-Scopol N (Hyoscine Butylbromide) based on pharmacodynamic effects, exposure modification, and administration constraints.

Documented Pharmacodynamic Interactions

Co-administration with several medicinal products may lead to an intensification of anticholinergic effects. This applies to classes such as tri- and tetracyclic antidepressants, antihistamines, and certain antipsychotics (e.g., phenothiazines and butyrophenones). Specific medicines including quinidine, amantadine, and disopyramide are also documented to intensify these effects. Conversely, dopamine antagonists like metoclopramide may cause a diminution of the effects of both substances on gastrointestinal motility. The tachycardic effects of beta-adrenergic agents may also be enhanced.

Constraints and Other Interactions

A critical, route-specific restriction exists for the injectable form: intramuscular administration is contraindicated in patients receiving anticoagulant drugs due to the documented risk of intramuscular haematoma. For oral administration, substances like antacids or adsorbent antidiarrheals may reduce the absorption of the medicine, which can affect therapeutic exposure. Regulatory patient information advises abstaining from alcohol as it may increase the chance of side effects such as drowsiness.

Advertisements

Mechanism of Action

How Boro-Scopol N Works: Mechanism of Action

Blocking Acetylcholine Signaling: The Core Anticholinergic Mechanism

The primary biological target involves the active ingredient, scopolamine, acting as a non-selective competitive antagonist at muscarinic acetylcholine receptors ( mAChRs) in both the central and peripheral nervous systems. This fundamental mechanism dampens signaling pathways that rely on the neurotransmitter acetylcholine ( ACh), which affects the autonomic regulation of muscle contraction and secretion.

Modulation of Smooth Muscle Tone and Glandular Output

This peripheral domain focuses on the downstream physiological effects arising from mAChR blockade, particularly M3 receptors in organs like the gastrointestinal and urinary tracts, as well as exocrine glands. By interrupting ACh-mediated signals for contraction and secretion, the mechanism produces the physiological effects of smooth muscle relaxation and a reduction in glandular output.

Central Alteration of Emetic Pathway Signals

This central domain involves scopolamine's ability to cross the blood-brain barrier to block mAChRs in the vestibular nuclei and the brain's vomiting center. This action interferes with the neural cascades that initiate the emetic reflex, resulting in the physiological consequence of altered signal transmission in the central vestibular and vomiting centers.

Advertisements

Dosage and Administration Information

How to Use Boro-Scopol N: Official Administration Guidelines

The administration of Boro-Scopol N (Hyoscine Butylbromide) follows specific parameters that define its route, dosage, frequency, and duration of use. The medication is available in two main forms: oral tablets and a sterile solution for injection suitable for intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes.


Administration Scope

The official dosing schedule for adults and adolescents (12 years and older) defines the oral tablet dose as 10 mg to 20 mg, repeated up to 3 or 4 times daily. For acute relief, the parenteral dose is typically 20 mg to 40 mg initially. The maximum daily dose for parenteral administration must not exceed 100 mg.

Age-Group Rules: The oral form is officially indicated for children 6 to 12 years at a dose of 10 mg three times daily, but it is not recommended for children under 6 years. No specific dosage adjustments for older adults are defined.


Procedural Constraints

Boro-Scopol N is designated for acute or episodic use only and must not be taken on a continuous daily basis for extended periods without medical supervision. For proper intake, tablets must be swallowed whole with water and should not be crushed or chewed. When administered intravenously, the injection must be performed slowly (e.g., over at least 3 minutes). Additionally, the IM route is generally restricted in patients receiving anticoagulant therapy, necessitating the use of the IV or SC route instead.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Boro-Scopol N

This overview summarizes the available research concerning Hyoscine Butylbromide (Boro-Scopol N), detailing the types of studies conducted and what the findings, observed in those specific research contexts, indicate about the drug's role in symptom management. It is based solely on clinical research reports and regulatory evaluations.


Evidence for Functional and Cramping Abdominal Pain

Research has primarily employed Randomized Controlled Trials (RCTs) to explore how symptoms change over time, focusing on outcomes related to physical discomfort. Findings describe measured symptom patterns observed in the study populations, with trials reporting differences in pain intensity scores between participants who received the agent and those who received a placebo in some settings. Uncertainty remains regarding the consistency of these patterns when the medicine was evaluated in emergency room patients compared to other pain protocols.


Evidence for Symptom Management in Irritable Bowel Syndrome (IBS)

For conditions where symptoms may vary in intensity, the evidence largely consists of RCTs examining patient-reported outcomes related to global symptom relief and abdominal discomfort. Research highlights measured changes during the study period, and these findings contributed to the overall evidence base for understanding abdominal discomfort and cramping. Evidence is limited in comparing this drug against some of the newer prescription agents used for IBS, and sustained management over years is not fully established.


Evidence for Acute Spasm and Dysmenorrhea

Research on acute, intense spasms (colic) involved RCTs using the injection formulation, studying pain scores and the requirement for rescue analgesic medications. Findings varied in some trials where measured outcomes were compared to other study agents. For Primary Dysmenorrhea, short-term, on-demand RCTs examined changes in pain intensity. One key research limitation is that the isolated contribution of the antispasmodic component is sometimes uncertain in studies that used it in combination with other pain relievers.


Research Gaps and Uncertainty

The research landscape primarily focuses on acute or short-to-intermediate-term symptom control, meaning long-term effects are not fully established. Data for special populations, such as older adults or patients with complex comorbidities, remain insufficient when compared to the general adult evidence base. A critical uncertainty is the comparative outcomes of this agent against other available smooth muscle relaxants; comparative evidence is lacking in many head-to-head scenarios.

Key Studies & References

  1. Real-world effects of hyoscine butylbromide combined with paracetamol in women with dysmenorrhea: a patient survey
  2. WHO Model List of Essential Medicines (Reference for therapeutic class and global use context)
  3. A Comprehensive Review of the Effects of Hyoscine Butylbromide in Childhood
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Boro-Scopol N (FAQ)


Q: Can Boro-Scopol N cause stomach upset or nausea?

Official information generally describes a low occurrence of gastrointestinal (GI) side effects. However, regulatory warnings instruct users to seek medical attention if they experience unexplained abdominal pain along with symptoms such as feeling sick or being sick (nausea/vomiting). This instruction is in place because these symptoms may indicate a serious underlying condition that requires medical assessment.


Q: How long does it take to start feeling the effects of Boro-Scopol N?

Clinical reviews and regulatory data indicate that the onset of action is generally fast after administration. For the oral tablet form, relief is often reported within 15 to 60 minutes. The injectable form is noted to act rapidly after administration.


Q: How long does Boro-Scopol N stay in your system after stopping?

Regulatory data on how the substance is cleared indicate a relatively short half-life of approximately 5 hours in healthy individuals. The drug is primarily designed to concentrate its effects directly at the site of action in the gut tissue.


Q: Is Boro-Scopol N a controlled substance?

This medicinal product is typically not classified as a controlled substance in major regulatory jurisdictions.


Q: Do I need to stop taking Boro-Scopol N suddenly, or should I taper off?

Official regulatory guidance advises that since this medicine is intended for acute or short-term use for spasms, it should be discontinued once the painful symptoms resolve. Regulatory guidance indicates that a tapering schedule is not standard practice for discontinuing use.


Q: How often do the side effects of Boro-Scopol N usually occur?

Official documents classify adverse reactions by frequency based on clinical study data. The most common effects, such as accommodation disorders (transient vision issues) or increased heart rate, occur in less than 1 in 10 people but more than 1 in 100 people.


Q: Are there different strengths or types of Boro-Scopol N available?

The medicine is generally available in two high-level forms. These include oral tablets and a sterile solution for injection. These forms are available in various strengths depending on the administration route.


Q: Does Boro-Scopol N require any special storage conditions?

Regulatory documents specify that the medicine should always be kept in its original package and stored out of the sight and reach of children. The oral tablets generally require protection from moisture.


Q: Is Boro-Scopol N used for preventing symptoms or just treating them?

Boro-Scopol N is officially indicated for the symptomatic treatment (relief) of acute pain associated with muscle spasms. Its regulatory purpose focuses on alleviating existing symptoms rather than long-term, continuous prevention.


Q: Are there any specific organs that Boro-Scopol N affects?

The primary action of the drug is focused on the smooth muscles of the body's internal, involuntary organs. Therefore, it principally affects the muscles of the gastrointestinal, biliary, and urinary tracts where spasms occur.


Q: Are there differences in how Boro-Scopol N affects men versus women?

Regulatory information specifically addresses eligibility concerning conditions that affect men, such as prostatic hypertrophy (enlarged prostate) causing urinary retention. Otherwise, documentation does not broadly detail sex-specific differences in effect.


Q: Does Boro-Scopol N require regular blood tests or monitoring?

Regulatory documents do not generally require routine blood tests for use. However, regulatory documents note that monitoring of heart rate and blood pressure may be required, particularly when the injectable form is administered to patients with pre-existing heart conditions.


Q: Is Boro-Scopol N available as a generic medicine?

Yes, the active ingredient, Hyoscine Butylbromide, is widely available in many jurisdictions. It is marketed by various companies under different brand names and is available as generic options.


Q: What is the chance of experiencing a rare but severe side effect from Boro-Scopol N?

Severe adverse events, such as anaphylactic shock (a very serious allergic reaction), are documented in post-marketing reports, particularly following injection. These reactions are officially classified as having a frequency that cannot be estimated, meaning they are considered rare events.


Q: Can Boro-Scopol N affect my mood or make me irritable?

Anticholinergic effects generally do not include mood changes or irritability in healthy adults taking the recommended dose. However, some regulatory documents note that older adults may experience excitement, agitation, or confusion, and children may rarely experience a paradoxical reaction called hyperexcitability.


Q: Are there any specific warnings for people with heart conditions?

Yes, regulatory information states that use is contraindicated (strictly prohibited) for individuals who have a pathological rapid heart rhythm, known as tachycardia. Caution and close monitoring are also advised for patients with other cardiac conditions like coronary heart disease or hypertension.


Q: What happens if I miss a scheduled time to take Boro-Scopol N?

Regulatory patient information describes a common approach where a forgotten dose is taken upon remembrance. If it is near the time of the next scheduled dose, information states to skip the missed dose and resume the regular schedule.


Q: Is Boro-Scopol N similar to over-the-counter flu medicine?

No. Boro-Scopol N is officially classified as an antispasmodic agent and is specifically indicated for the symptomatic treatment of muscle spasms in internal organs. It is not indicated or used for the general symptoms typically addressed by over-the-counter flu medicines.


Q: Why does Boro-Scopol N have to be prescribed?

The drug is designated as a prescription-only medicine in many regions due to regulatory requirements. This is typically due to the presence of important contraindications (conditions where it cannot be used) and the potential for serious, rare side effects, necessitating a professional medical evaluation before use.


Q: What is the main difference between Boro-Scopol N and regular Scopolamine?

Boro-Scopol N is a chemically modified version of Scopolamine. This modification (a quaternary ammonium compound) ensures that its therapeutic action remains primarily peripheral (in the gut and abdomen), with minimal ability to cross the blood-brain barrier and affect the central nervous system.


Q: Does taking Boro-Scopol N affect my ability to drive?

Yes, official labeling warns that side effects such as accommodation disorders (transient blurred vision) or dizziness can occur. If these effects are present, regulatory guidance advises against driving or operating machinery.


Advertisements

How should Boro-Scopol N be stored and disposed of?

How to Store and Dispose of Boro-Scopol N

Official regulatory guidelines for Boro-Scopol N (Hyoscine Butylbromide) specify mandatory storage and disposal conditions to maintain product quality and safety.

Required Storage and Handling

Requirement Rule
Temperature Store below the maximum temperature specified on the label, typically 25 C or 30 C for different formulations.
Protection Keep the medicine in its original package and protected from moisture.
Container Tablets must remain in the blister strip until use.
Child Safety Must be stored out of the sight and reach of children.
Injection Form The solution for injection must not be refrigerated or frozen and must be used immediately after opening the ampoule.

Official Disposal Instructions

Unused or expired Boro-Scopol N must be disposed of according to local regulations for pharmaceutical waste. The product must not be discarded into wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Boro-Scopol N found in:

A-Z Index: